{"meta":{"query_hash":"ef6dc853d087","filters":{"venue":"Precision Cancer Medicine"},"cohort_total":5,"direct_labels_cover":0,"predictions_cover":5,"exported":5,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/ef6dc853d087","api":"https://metacan.xera.ac/api/v1/cohort?venue=Precision+Cancer+Medicine"},"results":[{"id":"W3144883130","doi":"10.21037/pcm-20-58","title":"The role of immunotherapy in metastatic triple negative breast cancer: a narrative review of the current clinical trials","year":2021,"lang":"en","type":"review","venue":"Precision Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Triple-negative breast cancer; Immunotherapy; Metastatic breast cancer; Oncology; Medicine; Clinical trial; Breast cancer; Narrative; Narrative review; Internal medicine; Cancer; Cancer immunotherapy; Intensive care medicine; Art","score_opus":0.16181610135790667,"score_gpt":0.5293993507710599,"score_spread":0.36758324941315323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3144883130","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011721425,0.9989906,0.00005228266,0.00035622207,0.00012023584,0.00001876548,0.00003246366,0.000003536291,0.00030858233],"genre_scores_gemma":[0.0009164777,0.9979684,0.00016811068,0.0005580996,0.00017923127,0.00003612502,0.000056704495,0.0000021700907,0.00011472048],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992181,0.00023747871,0.0002197002,0.00008958401,0.00018272836,0.000052486826],"domain_scores_gemma":[0.9966574,0.0022810185,0.000431353,0.000053351843,0.00046430065,0.00011249404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025047674,0.00086041307,0.0026785668,0.0020652628,0.00032952536,0.0017600625,0.001374305,0.0013258342,0.0045656217],"category_scores_gemma":[0.0046346276,0.00033958218,0.0022124029,0.0021967639,0.0004692001,0.0018610583,0.000830223,0.001984433,0.0007784764],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005992881,0.0001153172,0.0003211851,0.14207323,0.0006899403,0.00014898766,0.00012991106,0.00041217057,0.0007261754,0.0022136813,0.026167002,0.8264032],"study_design_scores_gemma":[0.0004554134,0.001079745,0.002463512,0.20714027,0.0053033475,0.0016409173,0.00024420826,0.0003899535,0.0005638502,0.0031064316,0.7775404,0.00007199732],"about_ca_topic_score_codex":0.0006749443,"about_ca_topic_score_gemma":0.0016946557,"teacher_disagreement_score":0.0045656217,"about_ca_system_score_codex":0.00077830994,"about_ca_system_score_gemma":0.001945127,"threshold_uncertainty_score":0.015273571},"labels":[],"label_agreement":null},{"id":"W3145138207","doi":"10.21037/pcm-20-64","title":"A narrative review of immune checkpoint inhibitors in early stage triple negative breast cancer","year":2021,"lang":"en","type":"review","venue":"Precision Cancer Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Taxane; Triple-negative breast cancer; Pembrolizumab; Breast cancer; Atezolizumab; Internal medicine; Chemotherapy; Immune checkpoint; Population; Cancer","score_opus":0.04721812796156658,"score_gpt":0.3967856712577745,"score_spread":0.34956754329620787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145138207","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000086049185,0.99787414,0.000067563575,0.00063685304,0.0005713065,0.000014993004,0.00006532133,0.000005046512,0.0006787995],"genre_scores_gemma":[0.0005824493,0.9971342,0.00015024675,0.00069581607,0.0008562235,0.000026366648,0.00011177045,0.0000023777693,0.00044048388],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99956673,0.00009437839,0.00014764044,0.00006734018,0.000097937074,0.00002592133],"domain_scores_gemma":[0.99830496,0.0009980925,0.00032968968,0.000023949126,0.00026382843,0.00007952222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081999344,0.00081868726,0.0017360275,0.003720892,0.00036060292,0.0013515044,0.0009870849,0.0012276921,0.008526285],"category_scores_gemma":[0.0030141424,0.0003399445,0.0013041197,0.003208015,0.00035846466,0.0017746886,0.00079025823,0.0017235753,0.0016726204],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001704862,0.000051297386,0.00035116062,0.13110524,0.00026451555,0.0005723486,0.00015810654,0.00036391066,0.00058470457,0.0027345095,0.12753443,0.7361094],"study_design_scores_gemma":[0.000040761995,0.00013127449,0.001201497,0.06354859,0.000532303,0.0034502235,0.00010124014,0.00010892476,0.00014819688,0.0010710221,0.92963284,0.00003312141],"about_ca_topic_score_codex":0.001397287,"about_ca_topic_score_gemma":0.0028738095,"teacher_disagreement_score":0.008526285,"about_ca_system_score_codex":0.0009521228,"about_ca_system_score_gemma":0.0018936023,"threshold_uncertainty_score":0.028523326},"labels":[],"label_agreement":null},{"id":"W3159637394","doi":"10.21037/pcm-20-69","title":"A narrative review of chemotherapy in advanced triple negative breast cancer","year":2021,"lang":"en","type":"review","venue":"Precision Cancer Medicine","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Eribulin; Medicine; Oncology; Internal medicine; Triple-negative breast cancer; Breast cancer; Anthracycline; Taxane; Olaparib; Gemcitabine; Chemotherapy; Capecitabine; Metastatic breast cancer; Cancer; Colorectal cancer","score_opus":0.05870134318040379,"score_gpt":0.4804741947722393,"score_spread":0.42177285159183553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159637394","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000120218116,0.9979074,0.000059666007,0.00059618655,0.00031873668,0.000022614828,0.000085421816,0.0000032132602,0.0008865322],"genre_scores_gemma":[0.0011884063,0.9970752,0.00017861753,0.0007375682,0.00041595456,0.000042407704,0.00009678518,0.000002466596,0.00026260788],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99881727,0.0004227163,0.00039022267,0.00011957171,0.00020447074,0.00004583746],"domain_scores_gemma":[0.9946406,0.0039967075,0.000753144,0.000057272682,0.00047411514,0.00007810827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011671886,0.000845666,0.0015280902,0.0044807657,0.0004726602,0.0019605462,0.0008071728,0.001423643,0.0071396925],"category_scores_gemma":[0.0070252945,0.00036229947,0.0012427126,0.00447526,0.00050983176,0.0018000004,0.0009146341,0.0012900967,0.001173759],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018230852,0.000051837655,0.00046860706,0.35507816,0.00041759855,0.00090168486,0.0007433652,0.00036450004,0.00049520854,0.0055949283,0.09542999,0.5402719],"study_design_scores_gemma":[0.000029796889,0.00011500052,0.0013058641,0.23756811,0.00089555315,0.003246431,0.0003287734,0.00008002691,0.0001371652,0.0011877323,0.7550771,0.000028331055],"about_ca_topic_score_codex":0.0025061236,"about_ca_topic_score_gemma":0.004177316,"teacher_disagreement_score":0.0071396925,"about_ca_system_score_codex":0.0014866649,"about_ca_system_score_gemma":0.003239507,"threshold_uncertainty_score":0.023884594},"labels":[],"label_agreement":null},{"id":"W4285050759","doi":"10.21037/pcm-22-21","title":"Introduction to Management of Triple Negative Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Precision Cancer Medicine","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Triple-negative breast cancer; Cancer; Breast cancer; Medicine; Oncology; Internal medicine","score_opus":0.01129126158190201,"score_gpt":0.3013720399521503,"score_spread":0.29008077837024826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285050759","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041293595,0.65332884,0.023400808,0.24823093,0.0279367,0.00041548364,0.0014555529,0.0005853997,0.04051685],"genre_scores_gemma":[0.03249779,0.66491115,0.035603076,0.16366273,0.06479721,0.00086376024,0.0012555639,0.00022196486,0.03618686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993813,0.00025438203,0.00006596793,0.00011170166,0.0001437704,0.000042742126],"domain_scores_gemma":[0.9983387,0.000898404,0.00014662385,0.00007255182,0.0003424253,0.00020133016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014909996,0.0007589372,0.0007116578,0.00071369164,0.00046769634,0.0012334872,0.00087912777,0.0020151897,0.013234125],"category_scores_gemma":[0.0034097296,0.0003013662,0.0007466581,0.0004771684,0.0007196578,0.0011177964,0.0012022742,0.004083345,0.003906916],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040918274,0.00027277364,0.0019342577,0.0031957894,0.000110775734,0.0006846012,0.00015258358,0.00034145388,0.0021303126,0.013048175,0.25048485,0.72723526],"study_design_scores_gemma":[0.000118297736,0.00046726706,0.0052874372,0.0038238894,0.000086369226,0.002592969,0.00008365502,0.00017182813,0.0006718201,0.012478442,0.9741726,0.000045567536],"about_ca_topic_score_codex":0.0011770509,"about_ca_topic_score_gemma":0.0014827254,"teacher_disagreement_score":0.013234125,"about_ca_system_score_codex":0.0008330374,"about_ca_system_score_gemma":0.0011435879,"threshold_uncertainty_score":0.0442726},"labels":[],"label_agreement":null},{"id":"W4319454669","doi":"10.21037/pcm-22-39","title":"The role of concurrent amplification of PD-L1, PD-L2 and JAK2 in metastatic lung adenocarcinoma as a biomarker of immune checkpoint inhibitor response: a case report","year":2023,"lang":"en","type":"article","venue":"Precision Cancer Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"PD-L1; Biomarker; Adenocarcinoma; Cancer research; Immune checkpoint; Immune system; Immunotherapy; Lung cancer; Medicine; Oncology; Immunology; Cancer; Internal medicine; Biology; Genetics","score_opus":0.03174351883292337,"score_gpt":0.3968917742011644,"score_spread":0.365148255368241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319454669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700787,0.008878329,0.004992184,0.005671941,0.0003637616,0.0002599669,0.0003818281,0.00025281997,0.00912054],"genre_scores_gemma":[0.993952,0.0015607402,0.0021054205,0.00073434546,0.0007862982,0.000025144749,0.00008492418,0.00003160404,0.00071944285],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9987612,0.0001702247,0.00015693546,0.00036407565,0.0002116237,0.00033605887],"domain_scores_gemma":[0.99702245,0.0009725577,0.00059065555,0.00028043872,0.00021483556,0.0009189814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069327233,0.0020604813,0.0016793158,0.0037558293,0.0033344245,0.0029816236,0.0017460628,0.007870497,0.0021678486],"category_scores_gemma":[0.004104663,0.0018115169,0.0018305593,0.00172001,0.0023519045,0.0031310217,0.0022062308,0.0047476212,0.0011210674],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024022487,0.000016750755,0.0032053487,0.00002736668,0.000007480543,0.99513227,0.00013554371,0.000058006524,0.0005302451,0.00008526863,0.00015315322,0.0006244886],"study_design_scores_gemma":[0.000004265021,0.00002814079,0.0013062089,0.000010535993,0.000011967103,0.9976788,0.00008617366,0.0002485872,0.00028768994,0.00008246465,0.00024817954,0.000007069026],"about_ca_topic_score_codex":0.0034654285,"about_ca_topic_score_gemma":0.0040988335,"teacher_disagreement_score":0.007870497,"about_ca_system_score_codex":0.0021817104,"about_ca_system_score_gemma":0.0009988957,"threshold_uncertainty_score":0.015829504},"labels":[],"label_agreement":null}]}